166 related articles for article (PubMed ID: 37928523)
21. IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Chua CY; Liu Y; Granberg KJ; Hu L; Haapasalo H; Annala MJ; Cogdell DE; Verploegen M; Moore LM; Fuller GN; Nykter M; Cavenee WK; Zhang W
Oncogene; 2016 Feb; 35(6):738-47. PubMed ID: 25893308
[TBL] [Abstract][Full Text] [Related]
22. JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration.
Mendes KN; Wang GK; Fuller GN; Zhang W
Int J Oncol; 2010 Jul; 37(1):143-53. PubMed ID: 20514406
[TBL] [Abstract][Full Text] [Related]
23. Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.
Verma BK; Kondaiah P
J Neurooncol; 2020 Sep; 149(2):209-217. PubMed ID: 32803659
[TBL] [Abstract][Full Text] [Related]
24. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
25. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
Zheng S; Houseman EA; Morrison Z; Wrensch MR; Patoka JS; Ramos C; Haas-Kogan DA; McBride S; Marsit CJ; Christensen BC; Nelson HH; Stokoe D; Wiemels JL; Chang SM; Prados MD; Tihan T; Vandenberg SR; Kelsey KT; Berger MS; Wiencke JK
Neuro Oncol; 2011 Mar; 13(3):280-9. PubMed ID: 21339190
[TBL] [Abstract][Full Text] [Related]
26. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
27. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
28. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
30. Expression of insulin-like growth factor binding protein genes and its hypoxic regulation in U87 glioma cells depends on ERN1 mediated signaling pathway of endoplasmic reticulum stress.
Minchenko DO; Kharkova AP; Karbovskyi LL; Minchenko OH
Endocr Regul; 2015 Apr; 49(2):73-83. PubMed ID: 25960008
[TBL] [Abstract][Full Text] [Related]
31. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.
Liu Y; Li F; Yang YT; Xu XD; Chen JS; Chen TL; Chen HJ; Zhu YB; Lin JY; Li Y; Xie XM; Sun XL; Ke YQ
Oncogene; 2019 Mar; 38(11):1815-1831. PubMed ID: 30368528
[TBL] [Abstract][Full Text] [Related]
32. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
33. Expanding the scope of candidate prognostic marker IGFBP2 in glioblastoma.
Lindström MS
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31296788
[TBL] [Abstract][Full Text] [Related]
34. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment.
Fan P; Xia J; Zhou M; Zhuo C; He H
PeerJ; 2023; 11():e16066. PubMed ID: 37744243
[TBL] [Abstract][Full Text] [Related]
36. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
37. A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma.
Zhang C; Wang M; Ji F; Peng Y; Wang B; Zhao J; Wu J; Zhao H
Biomed Res Int; 2021; 2021():8872977. PubMed ID: 33553434
[TBL] [Abstract][Full Text] [Related]
38. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.
Müller S; Kohanbash G; Liu SJ; Alvarado B; Carrera D; Bhaduri A; Watchmaker PB; Yagnik G; Di Lullo E; Malatesta M; Amankulor NM; Kriegstein AR; Lim DA; Aghi M; Okada H; Diaz A
Genome Biol; 2017 Dec; 18(1):234. PubMed ID: 29262845
[TBL] [Abstract][Full Text] [Related]
39. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
40. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
